Schrödinger delivered strong Q1 results, with robust software growth and improving margins, despite a tough macro environment. Regulatory changes, especially the FDA's move away from animal testing, ...

Schrödinger's growth was soft in the third quarter, and the company's losses continue to grow due to investments in internal programs. Operating expenses are expected to level out going forward, ...